You wake up and feel a tickle in your throat. Your head hurts. You’re mildly annoyed as you get the kids ready for school and dress for work yourself. Meanwhile, an epic war is being fought, just below your skin. Millions are fighting and dying for you to be able to complain as you head out the door. So what, exactly, is your immune system? In Immune, Philipp Dettmer, the brains behind the most popular science channel on YouTube, takes listeners on a journey through the fortress of the human body and its defenses.

On July 4, 2012, the announcement came that one of the longest-running mysteries in physics had been solved: the Higgs boson, the missing piece in understanding why particles have mass, had finally been discovered. On the rostrum, surrounded by jostling physicists and media, was the particle’s retiring namesake—the only person in history to have an existing single particle named for them. Why Peter Higgs? Drawing on years of conversations with Higgs and others, Close illuminates how an unprolific man became one of the world’s most famous scientists.

A landmark collaboration between a thirty-year veteran of the CIA and a Pulitzer Prize-winning journalist, The Main Enemy is the inside story of the CIA-KGB spy wars, told through the actions of the men who fought them. Based on hundreds of interviews with operatives from both sides, The Main Enemy puts us inside the heads of CIA officers as they dodge surveillance and walk into violent ambushes in Moscow. This is the story of the generation of spies who came of age in the shadow of the Cuban missile crisis and rose to run the CIA and KGB in the last days of the Cold War.

In lyric, accessible prose, Carlo Rovelli invites us to consider questions about the nature of time that continue to puzzle physicists and philosophers alike. For most listeners, this is unfamiliar terrain. We all experience time, but the more scientists learn about it, the more mysterious it appears. We think of it as uniform and universal, moving steadily from past to future, measured by clocks. Rovelli tears down these assumptions one by one, revealing a strange universe where, at the most fundamental level, time disappears.

As the head of Open Learning at MIT, renowned professor Sanjay Sarma has a daunting job description: to fling open the doors of the MIT experience for the benefit of the wider world. But if you're going to undertake such an ambitious project, you first have to ask: How do we learn? What are the most effective ways of educating? And how can the science of learning transform education to unlock our potential, as individuals and across society?

Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing - atom by atom - both a new life-saving immunosuppressant drug and a drug to combat the virus that causes AIDS.

It is widely understood that Charles Darwin’s theory of evolution completely revolutionized the study of biology. Yet, according to David Sloan Wilson, the Darwinian revolution won’t be truly complete until it is applied more broadly - to everything associated with the words “human,” “culture,” and “policy.”

Powerful and accessible, A History of America in Ten Strikes challenges all of our contemporary assumptions around labor, unions, and American workers. In this brilliant book, labor historian Erik Loomis recounts ten critical workers’ strikes in American labor history that everyone needs to know about (and then provides an annotated list of the 150 most important moments in American labor history in the appendix).

A spectacular generational saga of the making (and undoing) of a family dynasty: the riveting untold story of the gilded Jewish Bagdadi Sassoons, who built a vast empire through global finance and trade—cotton, opium, shipping, banking—that reached across three continents and ultimately changed the destinies of nations. With full access to rare family photographs and archives.

The term metaverse is suddenly everywhere, from debates over Fortnite to the pages of the New York Times to the speeches of Mark Zuckerberg, who proclaimed in June 2021 that “the overarching goal” of Facebook is to “bring the metaverse to life”. But what, exactly, is the metaverse? As pioneering theorist and venture capitalist Matthew Ball explains, it is the successor to the mobile internet that has defined the last two decades.

An enthralling account of a modern voyage of discovery as we meet the clever, social birds of prey called caracaras, which puzzled Darwin, fascinate modern-day falconers, and carry secrets of our planet's deep past in their family history.

From an award-winning Fortune reporter, an explosive narrative investigation of the generic drug boom that reveals the life-threatening dangers posed by globalization - The Jungle for pharmaceuticals.

Millions of Americans suffer from hearing loss. Faced with the cost and stigma of hearing aids, the natural human tendency is to do nothing and hope for the best, usually while pretending that nothing is wrong. In Volume Control, David Owen argues this inaction comes with a huge social cost. He demystifies the science of hearing while encouraging listeners to get the treatment they need for hearing loss and protect the hearing they still have.

Beginning with opium, the “joy plant,” which has been used for 10,000 years, Thomas Hager tells a captivating story of medicine. His subjects include the largely forgotten female pioneer who introduced smallpox inoculation to Britain, the infamous knockout drops, the first antibiotic, which saved countless lives, the first antipsychotic, which helped empty public mental hospitals, Viagra, statins, and the new frontier of monoclonal antibodies. This is a deep, wide-ranging, and wildly entertaining book.

This Way to the Universe is a celebration of the astounding, ongoing scientific investigations that have revealed the nature of reality at its smallest, at its largest, and at the scale of our daily lives. The enigmas that Professor Michael Dine discusses are like landmarks on a fantastic journey to the edge of the universe. Asked where to find out about the big bang, dark matter, the Higgs boson particle - the long cutting edge of physics right now - Dine had no single book he could recommend. This is his accessible, authoritative, and up-to-date answer.

Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing - atom by atom - both a new life-saving immunosuppressant drug and a drug to combat the virus that causes AIDS.

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at a time of economic recession and declining technological competitiveness in the United States, the event ignited a period of speculative frenzy over biotechnology.

Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them.

Developing life-changing drugs is risky and expensive, but that’s not what makes them unaffordable. Drug pricing is a staple of every news cycle and political debate. And while we’ve struggled for decades to agree on solutions that serve all patients without jeopardizing the invention of new medicines, many Americans suffer because they can’t afford the drugs they need. Do we really have to choose between affordability and innovation?

In 1989, the charismatic Joshua Boger left Merck, then America's most admired business, to found a drug company that would challenge industry giants and transform health care. Barry Werth described the company's tumultuous early days during the AIDS crisis in The Billion-Dollar Molecule, a celebrated classic of science and business journalism. Now he returns to tell a riveting story of Vertex's bold endurance and eventual success.

Leading futurist and OneShared.World founder Jamie Metzl explores how genome sequencing, gene editing, artificial intelligence, and other technologies are not only changing our lives, but catalyzing each other in radical and accelerating ways. These technologies have the potential to improve our health, feed billions of people, supercharge our economies, and store essential information for millions of years, but can also—if we are not careful—do immeasurable harm.

Beginning with opium, the “joy plant,” which has been used for 10,000 years, Thomas Hager tells a captivating story of medicine. His subjects include the largely forgotten female pioneer who introduced smallpox inoculation to Britain, the infamous knockout drops, the first antibiotic, which saved countless lives, the first antipsychotic, which helped empty public mental hospitals, Viagra, statins, and the new frontier of monoclonal antibodies. This is a deep, wide-ranging, and wildly entertaining book.

Just as Steve Coll told the story of globalization through ExxonMobil and Andrew Ross Sorkin told the story of Wall Street excess through Too Big to Fail, Christopher Leonard’s Kochland uses the extraordinary account of how the biggest private company in the world grew to be that big to tell the story of modern corporate America.

Sand, salt, iron, copper, oil, and lithium. These fundamental materials have created empires, razed civilizations, and fed our ingenuity and greed for thousands of years. Without them, our modern world would not exist, and the battle to control them will determine our future. In Material World, Ed Conway embarks on an epic journey across continents, cultures, and epochs to reveal the underpinnings of modern life on Earth—traveling from the sweltering depths of the deepest mine in Europe to spotless silicon chip factories in Taiwan to the eerie green pools where lithium originates.

Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception―a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. His book is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk untried new therapies.

How did a simple commodity, once the prized monopoly of kings and princes, become an essential ingredient in the lives of millions, before mutating yet again into the cause of a global health epidemic? Prior to 1600, sugar was a costly luxury, the domain of the rich. But with the rise of the sugar colonies in the New World over the following century, sugar became cheap, ubiquitous, and an everyday necessity. Less than 50 years ago, few people suggested that sugar posed a global health problem.

The pharmaceutical drug discovery and development cycle is long and complex. This audiobook provides a concise overview of the whole process and offers insights into working in the pharmaceutical industry. It is ideal for individuals who are thinking about a career in this industry, as well as those who want to gain a general understanding of pharmaceutical drug discovery and development.

Ali Tamaseb has spent thousands of hours manually amassing what may be the largest dataset ever collected on start-ups, comparing billion-dollar start-ups with those that failed to become one - 30,000 data points on nearly every factor: number of competitors, market size, the founder’s age, his or her university’s ranking, quality of investors, fundraising time, and many, many more. And what he found looked far different than expected.

A vast and largely unseen transformation of how war is fought as profound as the invention of gunpowder or advent of the nuclear age is occurring. Flying cars that can land like helicopters, artificial intelligence-powered drones that can fly into buildings and map their interiors, microsatellites that can see through clouds and monitor rogue missile sites—all these and more are becoming part of America’s DIU-fast-tracked arsenal. Until recently, the Pentagon was known for its uncomfortable relationship with Silicon Valley and for slow-moving processes that acted as a brake on innovation.

Ever since he was a kid, kicking broken soccer balls on the run-down streets of East London, Gary Stevenson dreamed of something bigger. As luck would have it, he was good at numbers. At the London School of Economics, wearing tracksuits and sneakers, Stevenson shocked his posh classmates by winning a competition called “The Trading Game.” The prize? A golden ticket to a new life, as the youngest trader at Citibank.